内克塔治疗 NKTR 深 沪
等待开盘 10-06 09:30:00 美东时间
42.22
-1.360
-3.12%
华盛通- 最 高77.755
- 今 开43.50
- 成交量 153.66万股
- 最 低 41.35
- 昨 收 43.58
- 总市值 785.29万
- 52周最高 109.00
- 市盈率 静 --
- 换手率 826.10%
- 52周最低 33.40
- 委 比 -88.89%
- 总股本 0.00亿
- 历史最高 1670.40
- 量 比 0.62
- 振 幅 83.54%
- 历史最低 5.25
- 每 手 1
- 风险率 12.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data
Eli Lilly says Zepbound and Foundayo provide superior weight loss and blood sugar control over Novo Nordisk's semaglutide treatments.
09-29 21:23
AEVEX Stock Is Surging Thursday: Post-IPO Momentum Explained
AEVEX Corp (NYSE:AVEX) shares are trading higher on Thursday as traders keep leaning into the post-IPO momentum in a high-volatility phase.
04-23 22:48
Nektar Therapeutics Launches $250M Common Stock Offering
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public
04-21 04:02
TD Cowen Initiates Coverage On Nektar Therapeutics with Buy Rating
TD Cowen analyst Marc Frahm initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating.
03-17 22:45
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Nektar Therapeutics -Announces $300M Public Offering
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten
02-11 05:23
Where Nektar Therapeutics Stands With Analysts
In the preceding three months, 5 analysts have released ratings for Nektar Ther...
01-30 04:01
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data
Nektar Therapeutics stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin.
2025-12-23 05:19
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before eligibility adjustments.
2025-12-17 00:30
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
